MX2017003464A - Inhibidores de histona desmetilasa. - Google Patents

Inhibidores de histona desmetilasa.

Info

Publication number
MX2017003464A
MX2017003464A MX2017003464A MX2017003464A MX2017003464A MX 2017003464 A MX2017003464 A MX 2017003464A MX 2017003464 A MX2017003464 A MX 2017003464A MX 2017003464 A MX2017003464 A MX 2017003464A MX 2017003464 A MX2017003464 A MX 2017003464A
Authority
MX
Mexico
Prior art keywords
cancer
compositions
compounds
histone demethylase
useful
Prior art date
Application number
MX2017003464A
Other languages
English (en)
Spanish (es)
Inventor
Nie Zhe
Alan Stafford Jeffrey
Marvin Veal James
K Chen Young
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of MX2017003464A publication Critical patent/MX2017003464A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2017003464A 2014-09-16 2015-09-15 Inhibidores de histona desmetilasa. MX2017003464A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051268P 2014-09-16 2014-09-16
PCT/US2015/050289 WO2016044342A1 (en) 2014-09-16 2015-09-15 Histone demethylase inhibitors

Publications (1)

Publication Number Publication Date
MX2017003464A true MX2017003464A (es) 2017-07-13

Family

ID=55533770

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003464A MX2017003464A (es) 2014-09-16 2015-09-15 Inhibidores de histona desmetilasa.

Country Status (17)

Country Link
US (2) US9676770B2 (enExample)
EP (1) EP3193881B1 (enExample)
JP (1) JP6660060B2 (enExample)
KR (1) KR20170048590A (enExample)
CN (1) CN107073006A (enExample)
AU (1) AU2015317904A1 (enExample)
BR (1) BR112017005128A2 (enExample)
CA (1) CA2961525A1 (enExample)
CL (1) CL2017000643A1 (enExample)
CO (1) CO2017002772A2 (enExample)
EA (1) EA201790502A1 (enExample)
EC (1) ECSP17020172A (enExample)
ES (1) ES2911292T3 (enExample)
IL (1) IL251103A0 (enExample)
MX (1) MX2017003464A (enExample)
SG (1) SG11201702108PA (enExample)
WO (1) WO2016044342A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903081A1 (en) 2013-03-14 2014-09-25 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CA2961525A1 (en) * 2014-09-16 2016-03-24 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
RS63359B1 (sr) 2015-11-06 2022-07-29 Incyte Corp Heterociklična jedinjenja kao inhibitori pi3k-gama
ES2995198T3 (en) 2016-01-05 2025-02-07 Incyte Corp Pyridine compounds as pi3k-gamma inhibitors
JP6970680B2 (ja) * 2016-03-15 2021-11-24 セルジーン クオンティセル リサーチ,インク. ヒストンデメチラーゼ阻害剤
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為PI3K-γ抑制劑之雜環化合物
KR102717072B1 (ko) 2017-10-18 2024-10-15 인사이트 코포레이션 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN111116571B (zh) * 2019-12-27 2022-07-12 吉首大学 含恶唑及三唑双杂环的化合物及其制备与应用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038683A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
CN1503673A (zh) 2000-10-26 2004-06-09 �㽭�пؼ����ɷ����޹�˾ 消炎药
GB0217780D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
US20040127733A1 (en) 2002-10-31 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
DE102004021779A1 (de) 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2007071653A1 (en) 2005-12-19 2007-06-28 Boehringer Ingelheim International Gmbh Use of aminoalcohol derivatives for the treatment of overactive bladder
DE602008005786D1 (de) 2007-10-03 2011-05-05 Vertex Pharma C-met-proteinkinasehemmer
DE102009019962A1 (de) 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
UA102336C2 (uk) 2009-11-10 2013-06-25 Пфайзер Інк. N1-ПІРАЗОЛСПІРОКЕТОНИ ЯК ІНГІБІТОРИ АЦЕТИЛ-СоА-КАРБОКСИЛАЗ
KR101781663B1 (ko) 2010-01-13 2017-09-25 템페로 파마슈티칼즈, 인크. 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
CA2903081A1 (en) * 2013-03-14 2014-09-25 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9896436B2 (en) * 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CA2961525A1 (en) 2014-09-16 2016-03-24 Celgene Quanticel Research, Inc. Histone demethylase inhibitors

Also Published As

Publication number Publication date
US10071984B2 (en) 2018-09-11
US20170240529A1 (en) 2017-08-24
CA2961525A1 (en) 2016-03-24
CO2017002772A2 (es) 2017-06-09
WO2016044342A1 (en) 2016-03-24
US9676770B2 (en) 2017-06-13
EA201790502A1 (ru) 2017-10-31
ES2911292T3 (es) 2022-05-18
BR112017005128A2 (pt) 2018-07-31
IL251103A0 (en) 2017-04-30
JP6660060B2 (ja) 2020-03-04
EP3193881B1 (en) 2022-02-09
CN107073006A (zh) 2017-08-18
SG11201702108PA (en) 2017-04-27
US20160108033A1 (en) 2016-04-21
JP2017527590A (ja) 2017-09-21
AU2015317904A1 (en) 2017-04-06
CL2017000643A1 (es) 2017-12-01
KR20170048590A (ko) 2017-05-08
EP3193881A1 (en) 2017-07-26
EP3193881A4 (en) 2018-02-21
ECSP17020172A (es) 2017-05-31

Similar Documents

Publication Publication Date Title
TW201613882A (en) Histone demethylase inhibitors
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
SA515360657B1 (ar) مثبطات ديميثيلاز هيستون
MX381597B (es) Inhibidores demetilasa-1 específica de lisina.
MX376632B (es) Inhibidores de demetilasa-1 especifica de lisina.
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
MX395534B (es) Inhibidores de demetilasa-1 especifica de lisina.
MX2015007205A (es) Inhibidores de la desmetilasa de histona.
MX391865B (es) Inhibidores de demetilasa-1 especifica de lisina.
EA201790502A1 (ru) Ингибиторы гистоновых диметилаз
MY201783A (en) Compositions and methods for inhibiting arginase activity
MX2017003466A (es) Inhibidores de histona desmetilasa.
MX366875B (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
MX2017003463A (es) Inhibidores de histona desmetilasa.